Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Prescient Therapeutics Limited ABN/ARBN Financial year ended: 56 006 569 106 30 June...
Appendix 4G and Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- June 2026 Quarterly Update and Appendix 4C
- March 2026 Quarterly Update and Appendix 4C
- Appendix 4D and Half Year Financial Report
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
Later from Prescient Therapeutics
- Appendix 4E and 2026 Annual Report
- Prescient Therapeutics Launches Share Purchase Plan for $7m
- Proposed issue of securities - PTX
- Share Purchase Plan Cleansing Notice
- Prescient Therapeutics Opens SPP to Raise $7m Today
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics